PTPN3

Summary

PTPN3 (protein tyrosine phosphatase non-receptor type 3, HGNC:9655) is a protein-coding gene on chromosome 9q31.3, encoding Tyrosine-protein phosphatase non-receptor type 3 (P26045). May act at junctions between the membrane and the cytoskeleton.

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This protein contains a C-terminal PTP domain and an N-terminal domain homologous to the band 4.1 superfamily of cytoskeletal-associated proteins. P97, a cell cycle regulator involved in a variety of membrane related functions, has been shown to be a substrate of this PTP. This PTP was also found to interact with, and be regulated by adaptor protein 14-3-3 beta. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 5774 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 36
• Clinical variants (ClinVar): 175 total
• Phenotypes (HPO): 8
• Druggable target: yes
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 1 cancer types
• MANE Select transcript: NM_002829

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9655
Approved symbol	PTPN3
Name	protein tyrosine phosphatase non-receptor type 3
Location	9q31.3
Locus type	gene with protein product
Status	Approved
Aliases	PTPH1
Ensembl gene	ENSG00000070159
Ensembl biotype	protein_coding
OMIM	176877
Entrez	5774

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 12 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000262539, ENST00000374541, ENST00000412145, ENST00000446349, ENST00000447271, ENST00000497739, ENST00000865410, ENST00000865411, ENST00000865412, ENST00000865413, ENST00000865414, ENST00000865415, ENST00000865416, ENST00000865417

RefSeq mRNA: 6 — MANE Select: NM_002829 NM_001145368, NM_001145369, NM_001145370, NM_001145371, NM_001145372, NM_002829

CCDS: CCDS48000, CCDS48001, CCDS6776

Canonical transcript exons

ENST00000374541 — 26 exons

Exon	Start	End
ENSE00000806055	109420424	109420600
ENSE00000806056	109422718	109422852
ENSE00000983477	109428621	109428684
ENSE00000983478	109426950	109427122
ENSE00001090538	109389233	109389379
ENSE00001090539	109406462	109406618
ENSE00001090542	109383423	109383551
ENSE00001090545	109404448	109404608
ENSE00001463784	109375700	109379633
ENSE00001463801	109498219	109498307
ENSE00001606103	109438114	109438234
ENSE00001625396	109445240	109445292
ENSE00001689765	109454496	109454574
ENSE00001747223	109436883	109436970
ENSE00001750132	109433073	109433161
ENSE00001788195	109448811	109448855
ENSE00003497921	109410229	109410415
ENSE00003516468	109408321	109408377
ENSE00003528171	109409999	109410076
ENSE00003580705	109391138	109391199
ENSE00003604086	109391471	109391561
ENSE00003716139	109382302	109382447
ENSE00003720438	109457173	109457215
ENSE00003730229	109381652	109381787
ENSE00003737404	109463297	109463451
ENSE00003748211	109457292	109457399

Expression profiles

Bgee: expression breadth ubiquitous, 264 present calls, max score 96.95.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.4441 / max 178.5957, expressed in 1024 samples.

FANTOM5 promoters (16 alternative TSS)

Promoter ID	TPM avg	Samples expressed
101904	5.4412	994
101902	0.2672	144
101905	0.2025	116
101898	0.1394	16
101896	0.0838	12
101903	0.0735	21
101897	0.0662	7
101895	0.0374	8
101900	0.0297	12
101906	0.0276	11

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	96.95	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	96.24	gold quality
secondary oocyte	CL:0000655	96.20	gold quality
triceps brachii	UBERON:0001509	95.58	gold quality
gluteal muscle	UBERON:0002000	95.32	gold quality
lower esophagus mucosa	UBERON:0035834	95.26	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.15	gold quality
diaphragm	UBERON:0001103	95.04	gold quality
lateral nuclear group of thalamus	UBERON:0002736	94.77	gold quality
gastrocnemius	UBERON:0001388	93.91	gold quality
biceps brachii	UBERON:0001507	93.82	gold quality
apex of heart	UBERON:0002098	93.77	gold quality
skeletal muscle tissue	UBERON:0001134	93.38	gold quality
vastus lateralis	UBERON:0001379	93.30	gold quality
muscle organ	UBERON:0001630	92.99	gold quality
skeletal muscle organ	UBERON:0014892	92.98	gold quality
muscle of leg	UBERON:0001383	92.90	gold quality
right lobe of liver	UBERON:0001114	92.81	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	92.80	gold quality
quadriceps femoris	UBERON:0001377	92.72	gold quality
metanephros cortex	UBERON:0010533	92.34	gold quality
amniotic fluid	UBERON:0000173	92.17	gold quality
nasal cavity epithelium	UBERON:0005384	91.75	gold quality
corpus epididymis	UBERON:0004359	91.70	gold quality
upper arm skin	UBERON:0004263	91.32	gold quality
adult mammalian kidney	UBERON:0000082	91.07	gold quality
islet of Langerhans	UBERON:0000006	91.05	gold quality
deltoid	UBERON:0001476	91.02	silver quality
heart left ventricle	UBERON:0002084	90.10	gold quality
skin of leg	UBERON:0001511	89.91	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	13.19

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

233 targeting PTPN3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-9-5P	100.00	72.28	2361
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-9718	99.94	68.91	918
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-145-5P	99.92	71.13	1836

Literature-anchored findings (GeneRIF, showing 30)

• regulates TACE (tnf-alpha convertase} (PMID:12207026)
• first reported demonstration that protein tyrosine phosphatase H1(PTPH1) is capable of interacting with and dephosphorylating T cell receptor zeta subunit (PMID:14672952)
• PTPH1 binds to the PDZ-domain binding motif of the cardiac voltage-gated sodium channel Na(v)1 and regulates the activity of Na(v)1. (PMID:16930557)
• Degradation of PTPN3 by HPV-16 E6 requires E6AP, the proteasome, and an interaction between the carboxy terminus of E6 and the PDZ domain of PTPN3. (PMID:17166906)
• phosphatase activity and FERM domain of PTPN3 are essential for its suppression of HBV gene expression. (PMID:17588219)
• PTP-H1 has a role in modulating GHR signaling and systemic growth through insulin-like growth factor 1 secretion (PMID:17921143)
• Data suggest that reducing the level of PTPH1 may contribute to the oncogenic activity of high-risk genital E6 proteins. (PMID:17947517)
• PTPH1 plays a role in Ras-dependent malignant growth by a mechanism depending on its p38gamma-binding activity. Ras increases p38gamma and PTPH1 expression and there is a coupling of increased p38gamma and PTPH1 protein expression in colon cancer. (PMID:20332238)
• PTPH1 stimulated breast cancer growth through regulating vitamin D receptor expression. PTPH1 was overexpressed in primary breast cancer and levels of its protein expression positively correlated with clinical metastasis. (PMID:21119599)
• The fusion transcript of ALK and PTPN3 identified resulted from translocation of a part of ALK gene into the third intron of PTPN3. Analysis of the transcript sequence indicates that no protein with any enzymatic activity is produced. (PMID:22334442)
• p38gamma Mitogen-activated protein kinase signals through phosphorylating its phosphatase PTPH1 in regulating ras protein oncogenesis and stress response. (PMID:22730326)
• These studies thus identified PTPH1 as a novel ER phosphatase and further demonstrate a therapeutic potential of enhancing breast cancer sensitivity to antiestrogens through dephosphorylating ER by PTPH1. (PMID:24227889)
• Activating mutations in and high expression levels of PTPN3 were associated with tumor recurrence in cholangiocarcinoma. (PMID:24503127)
• Results indicate that protein tyrosine phosphatase non-receptor type 3 (PTPN3) may act as a tumor suppressor in lung cancer through its modulation of epidermal growth factor receptor (EGFR) signaling. (PMID:25263444)
• analysis of how allosteric regulation of p38gamma and PTPN3 involves a PDZ domain-modulated complex formation (PMID:25314968)
• PTPN3 promotes tumorigenicity, stemness and drug resistance in ovarian cancer. (PMID:27833130)
• PTPH1 is upregulated in breast cancer from Indian population; its expression is correlative with ER, and PR status. The 2 kb region upstream of PTPH1 gene harbored CpG sites within, and was ubiquitously methylated in breast cancer. (PMID:30189107)
• High expression of PTPN3 was significantly associated with unfavorable prognosis of GBM. Moreover, in GBM cell lines, PTPN3 promoted cell proliferation and invasion, and the PTP common inhibitor pervanadate suppressed GBM proliferation and invasion. (PMID:30348936)
• E6 oncoprotein of the betaHPV type 8-mediated targeting of PTPH1 might result in higher level of EGFR and enhanced keratinocyte proliferation. (PMID:30875834)
• Structural and functional characterization of the PDZ domain of the human phosphatase PTPN3 and its interaction with the human papillomavirus E6 oncoprotein. (PMID:31092861)
• Study reports that PTPN3 suppresses liver cancer progression through positively regulating TGF-b signaling. Furthermore, the recurrent L232R mutation in liver cancer disables its role in enhancing TGF-beta signaling and abolishes its tumor-suppressive function. (PMID:31304624)
• findings reveal a novel mechanism by which reversible tyrosine phosphorylation of DAAM1 by Src and PTPN3 regulates actin dynamics and lung cancer invasivenes (PMID:31406243)
• PTPN3 suppressed the proliferation of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation and arresting cell cycle. (PMID:31706106)
• Low PTPN3 expression is associated with gastric cancer angiogenesis. (PMID:31972307)
• PTPN3 Inhibits the Growth and Metastasis of Clear Cell Renal Cell Carcinoma via Inhibition of PI3K/AKT Signaling. (PMID:32169891)
• NFkappaB and TGFbeta contribute to the expression of PTPN3 in activated human lymphocytes. (PMID:33137650)
• Molecular basis of the interaction of the human tyrosine phosphatase PTPN3 with the hepatitis B virus core protein. (PMID:33441627)
• PTPN3 Could Betae a Therapeutic Target of Pancreatic Cancer. (PMID:35641270)
• Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy. (PMID:38173048)
• Inhibition of PTPN3 Expressed in Activated Lymphocytes Enhances the Antitumor Effects of Anti-PD-1 Therapy in Head and Neck Cancer, Especially in Hypoxic Environments. (PMID:38297883)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ptpn3	ENSDARG00000055784
mus_musculus	Ptpn3	ENSMUSG00000038764
rattus_norvegicus	Ptpn3	ENSRNOG00000011425

Paralogs (35): PTPRN (ENSG00000054356), PTPRU (ENSG00000060656), PTPN21 (ENSG00000070778), PTPN18 (ENSG00000072135), PTPN23 (ENSG00000076201), PTPRH (ENSG00000080031), PTPRC (ENSG00000081237), PTPN4 (ENSG00000088179), PTPRS (ENSG00000105426), PTPRZ1 (ENSG00000106278), PTPN5 (ENSG00000110786), PTPN6 (ENSG00000111679), PTPRB (ENSG00000127329), PTPN12 (ENSG00000127947), PTPRE (ENSG00000132334), PTPRA (ENSG00000132670), PTPN22 (ENSG00000134242), PTPRF (ENSG00000142949), PTPN7 (ENSG00000143851), PTPRG (ENSG00000144724), PTPRJ (ENSG00000149177), PTPRO (ENSG00000151490), PTPN14 (ENSG00000152104), PTPRK (ENSG00000152894), PTPRR (ENSG00000153233), PTPRD (ENSG00000153707), PTPRN2 (ENSG00000155093), PTPN13 (ENSG00000163629), PTPN9 (ENSG00000169410), PTPRM (ENSG00000173482), PTPN2 (ENSG00000175354), PTPN11 (ENSG00000179295), PTPRT (ENSG00000196090), PTPN1 (ENSG00000196396), PTPN20 (ENSG00000204179)

Protein

Protein identifiers

Tyrosine-protein phosphatase non-receptor type 3 — P26045 (reviewed: P26045)

Alternative names: Protein-tyrosine phosphatase H1

All UniProt accessions (2): P26045, J3KN34

UniProt curated annotations — full annotation on UniProt →

Function. May act at junctions between the membrane and the cytoskeleton. Possesses tyrosine phosphatase activity.

Subcellular location. Cell membrane. Cytoplasm. Cytoskeleton.

Similarity. Belongs to the protein-tyrosine phosphatase family. Non-receptor class subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
P26045-1	1	yes
P26045-2	2
P26045-3	3

RefSeq proteins (6): NP_001138840, NP_001138841, NP_001138842, NP_001138843, NP_001138844, NP_002820* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000242	PTP_cat	Domain
IPR000299	FERM_domain	Domain
IPR000387	Tyr_Pase_dom	Domain
IPR001478	PDZ	Domain
IPR003595	Tyr_Pase_cat	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR012151	Tyr_Pase_non-rcpt_typ-3/4	Family
IPR014352	FERM/acyl-CoA-bd_prot_sf	Homologous_superfamily
IPR016130	Tyr_Pase_AS	Active_site
IPR018979	FERM_N	Domain
IPR018980	FERM_PH-like_C	Domain
IPR019747	FERM_CS	Conserved_site
IPR019748	FERM_central	Domain
IPR019749	Band_41_domain	Domain
IPR029021	Prot-tyrosine_phosphatase-like	Homologous_superfamily
IPR029071	Ubiquitin-like_domsf	Homologous_superfamily
IPR035963	FERM_2	Homologous_superfamily
IPR036034	PDZ_sf	Homologous_superfamily
IPR041783	PTPN3/4_FERM_C	Domain

Pfam: PF00102, PF00373, PF00595, PF09379, PF09380

Enzyme classification (BRENDA):

• EC 3.1.3.48 — protein-tyrosine-phosphatase (BRENDA: 59 organisms, 501 substrates, 1326 inhibitors, 270 Km, 165 kcat entries)

Substrate kinetics (BRENDA)

70 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
4-NITROPHENYL PHOSPHATE	0.0008–148	84
6,8-DIFLUORO-4-METHYLUMBELLIFERYL PHOSPHATE	0.0039–0.862	27
P-NITROPHENYL PHOSPHATE	0.0024–10	20
DADEPYLIPQQG	0.0003–0.1	12
PHOSPHOTYROSINE	0.012–30	11
LYSOZYME	0.0003–0.012	5
MYELIN BASIC PROTEIN	0.0001–0.022	5
ACETYL-DADEPY-NH2	0.0228–0.219	4
ACETYL-DADEPYL-NH2	1.1–97.5	4
4,6,8-TRIMETHYL-2-OXO-2H-CHROMEN-7-YL DIHYDROGEN	0.02–0.156	3
SASASPYSASA	0.53–2.3	3
1-NAPHTHYL PHOSPHATE	1.19–1.88	2
3,6-FLUORESCEIN DIPHOSPHATE	15–19	2
4-METHYLUMBELLIFERYL PHOSPHATE	0.953–2.41	2
BOVINE SERUM ALBUMIN	0.0001–0.0003	2

Catalyzed reactions (Rhea), 1 shown:

• O-phospho-L-tyrosyl-[protein] + H2O = L-tyrosyl-[protein] + phosphate (RHEA:10684)

UniProt features (65 total): strand 22, helix 13, modified residue 6, sequence variant 5, domain 3, binding site 3, turn 3, compositionally biased region 3, splice variant 2, region of interest 2, chain 1, sequence conflict 1, active site 1

Structure

Experimental structures (PDB)

13 structures.

PDB	Method	Resolution (Å)
4RI5	X-RAY DIFFRACTION	1.26
2B49	X-RAY DIFFRACTION	1.54
4RHG	X-RAY DIFFRACTION	1.58
4RI4	X-RAY DIFFRACTION	1.6
4RH9	X-RAY DIFFRACTION	1.6
4RH5	X-RAY DIFFRACTION	1.6
8CQY	X-RAY DIFFRACTION	1.7
4S0G	X-RAY DIFFRACTION	1.72
4QUN	X-RAY DIFFRACTION	1.86
6T36	X-RAY DIFFRACTION	1.86
8OEP	X-RAY DIFFRACTION	1.87
6HKS	X-RAY DIFFRACTION	2.19
4QUM	X-RAY DIFFRACTION	2.52

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P26045-F1	73.85	0.42

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 842 (phosphocysteine intermediate)

Ligand- & substrate-binding residues (3): 811; 842–848; 886

Post-translational modifications (6): 357, 359, 367, 376, 381, 425

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-182971	EGFR downregulation
R-HSA-5675221	Negative regulation of MAPK pathway

MSigDB gene sets: 279 (showing top): GOBP_MEMBRANE_DEPOLARIZATION, GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, GOBP_REGULATION_OF_ERBB_SIGNALING_PATHWAY, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_SODIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_ERBB_SIGNALING_PATHWAY, GOBP_MEMBRANE_DEPOLARIZATION_DURING_ACTION_POTENTIAL, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_REGULATION_OF_MEMBRANE_DEPOLARIZATION, BONCI_TARGETS_OF_MIR15A_AND_MIR16_1, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_MONOATOMIC_CATION_TRANSPORT, HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP, ATGTTAA_MIR302C, GOBP_REGULATION_OF_SODIUM_ION_TRANSPORT

GO Biological Process (8): MAPK cascade (GO:0000165), negative regulation of epidermal growth factor receptor signaling pathway (GO:0042059), negative regulation of mitotic cell cycle (GO:0045930), negative regulation of membrane protein ectodomain proteolysis (GO:0051045), regulation of membrane depolarization during action potential (GO:0098902), regulation of sodium ion transmembrane transport (GO:1902305), protein dephosphorylation (GO:0006470), dephosphorylation (GO:0016311)

GO Molecular Function (8): phosphotyrosine residue binding (GO:0001784), protein tyrosine phosphatase activity (GO:0004725), cytoskeletal protein binding (GO:0008092), sodium channel regulator activity (GO:0017080), ATPase binding (GO:0051117), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (6): cytoplasm (GO:0005737), cytosol (GO:0005829), cytoskeleton (GO:0005856), plasma membrane (GO:0005886), cytoplasmic side of plasma membrane (GO:0009898), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Signaling by EGFR	1
RAF/MAP kinase cascade	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
intracellular signaling cassette	1
epidermal growth factor receptor signaling pathway	1
regulation of epidermal growth factor receptor signaling pathway	1
negative regulation of ERBB signaling pathway	1
mitotic cell cycle	1
regulation of mitotic cell cycle	1
negative regulation of cell cycle	1
membrane protein ectodomain proteolysis	1
negative regulation of protein catabolic process	1
negative regulation of proteolysis	1
regulation of membrane protein ectodomain proteolysis	1
regulation of membrane depolarization	1
membrane depolarization during action potential	1
regulation of sodium ion transport	1
sodium ion transmembrane transport	1
regulation of monoatomic cation transmembrane transport	1
dephosphorylation	1
protein modification process	1
phosphate-containing compound metabolic process	1
protein phosphorylated amino acid binding	1
phosphoprotein phosphatase activity	1
protein binding	1
sodium channel activity	1
ion channel regulator activity	1
enzyme binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1
intracellular membraneless organelle	1
membrane	1
cell periphery	1
plasma membrane	1
cytoplasmic side of membrane	1

Protein interactions and networks

STRING

1094 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PTPN3	PTS	Q03393	852
PTPN3	DLG1	Q12959	656
PTPN3	VCP	P55072	574
PTPN3	UBE3A	P78355	554
PTPN3	BET1L	Q9NYM9	545
PTPN3	VCPIP1	Q96JH7	524
PTPN3	NPLOC4	Q8TAT6	523
PTPN3	IGDCC3	Q8IVU1	522
PTPN3	MPDZ	O75970	504
PTPN3	NHERF2	Q15599	502
PTPN3	TP53	P04637	490
PTPN3	DTNB	O60941	485
PTPN3	ALK	Q9UM73	483
PTPN3	SCN5A	Q14524	482
PTPN3	DMD	P11532	464

IntAct

503 interactions, top by confidence:

A	B	Type	Score
PTPN3	YWHAQ	psi-mi:“MI:2364”(proximity)	0.850
PTPN3	VANGL1	psi-mi:“MI:0915”(physical association)	0.750
VANGL1	PTPN3	psi-mi:“MI:0407”(direct interaction)	0.750
PTPN3	LMO1	psi-mi:“MI:0915”(physical association)	0.720
PTPN3	AKR1C1	psi-mi:“MI:0915”(physical association)	0.720
WDR6	PTPN3	psi-mi:“MI:0915”(physical association)	0.720
AKR1C1	PTPN3	psi-mi:“MI:0915”(physical association)	0.720
LMO1	PTPN3	psi-mi:“MI:0915”(physical association)	0.720
PTPN3	WDR6	psi-mi:“MI:0915”(physical association)	0.720
SCN5A	PTPN3	psi-mi:“MI:0407”(direct interaction)	0.670
PTPN3	MCC	psi-mi:“MI:0914”(association)	0.660
PTPN3	MCC	psi-mi:“MI:0915”(physical association)	0.660
MCC	PTPN3	psi-mi:“MI:0407”(direct interaction)	0.660
PTPN3	GHR	psi-mi:“MI:0407”(direct interaction)	0.650
PTPN3	GHR	psi-mi:“MI:0203”(dephosphorylation reaction)	0.650
PTPN3	GHR	psi-mi:“MI:0915”(physical association)	0.650
EPS15	PTPN3	psi-mi:“MI:0407”(direct interaction)	0.650
PTPN3	EPS15	psi-mi:“MI:0915”(physical association)	0.650
PTPN3	EPS15	psi-mi:“MI:0407”(direct interaction)	0.650
PTPN3	EPS15	psi-mi:“MI:0203”(dephosphorylation reaction)	0.650
PTPN3	MAPK12	psi-mi:“MI:0203”(dephosphorylation reaction)	0.620
MAPK12	PTPN3	psi-mi:“MI:0407”(direct interaction)	0.620
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610

BioGRID (208): PTPN3 (Two-hybrid), PTPN3 (Two-hybrid), WDR6 (Two-hybrid), DIP2A (Two-hybrid), ZCCHC10 (Two-hybrid), NXT2 (Two-hybrid), PTPN3 (Two-hybrid), PTPN3 (Two-hybrid), ACOT8 (Affinity Capture-MS), KCTD3 (Affinity Capture-MS), SHKBP1 (Affinity Capture-MS), SLC1A5 (Affinity Capture-MS), SRRM2 (Affinity Capture-MS), VANGL1 (Affinity Capture-MS), YWHAB (Affinity Capture-MS)

ESM2 similar proteins: A0A0G2JXT6, A0JMF6, A0JMK5, A2ALK8, A2BGG1, A6QLT4, A7MB43, G5ED68, O13819, O14830, P26045, P33402, P51432, Q09M05, Q13496, Q13613, Q15111, Q3USB7, Q4KWH5, Q4R6N0, Q4U2V3, Q52KU6, Q5EB32, Q5F452, Q5R6F6, Q5R9S3, Q5U581, Q62688, Q6AXQ4, Q6NU08, Q6TEL0, Q6XPS3, Q7TPM9, Q7ZXF1, Q8K394, Q8NCE2, Q8VE11, Q8VEL2, Q96EF0, Q96MI9

Diamond homologs: A0A6I8TCE0, A1L1L3, A2ALK8, A4IFW2, B0V2N1, B0X4T2, B1AUH1, B2GV87, B2RU80, B3DK56, B9EKR1, E9Q0N2, E9Q612, F1NWE3, G5EC24, G5EGJ9, H2KZM6, O02695, O08617, O13016, O35239, O55082, P06800, P16620, P17706, P18031, P18052, P18433, P20417, P23467, P23468, P23469, P23470, P23471, P26045, P28191, P29074, P29350, P29351, P29352

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
PTPN3	“down-regulates activity”	VCP	dephosphorylation
PTPN3	“up-regulates activity”	ESR1	dephosphorylation
MAP3K7	unknown	PTPN3	phosphorylation
PTPN3	“down-regulates activity”	GHR	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 136 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	6	49.6×	3e-07
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	43.8×	3e-07
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	6	43.8×	3e-07
Activation of BH3-only proteins	6	32.4×	2e-06
RHO GTPases activate PKNs	6	20.7×	3e-05
Intrinsic Pathway for Apoptosis	6	19.1×	4e-05
RND2 GTPase cycle	6	16.9×	6e-05
RND1 GTPase cycle	5	14.4×	6e-04

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	14.3×	8e-03
transport across blood-brain barrier	7	9.8×	7e-03
intracellular protein localization	8	6.5×	8e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 1 cancer types — PAAD.

Clinical variants and AI predictions

ClinVar

175 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	138
Likely benign	6
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

4499 predictions. Top by Δscore:

Variant	Effect	Δscore
9:109379559:A:C	donor_gain	1.0000
9:109381646:ACT:A	donor_loss	1.0000
9:109381647:CTC:C	donor_loss	1.0000
9:109381647:CTCA:C	donor_gain	1.0000
9:109381648:TCACT:T	donor_loss	1.0000
9:109381649:CACTG:C	donor_loss	1.0000
9:109381650:A:AC	donor_gain	1.0000
9:109381651:C:CG	donor_gain	1.0000
9:109381651:CTG:C	donor_gain	1.0000
9:109381651:CTGA:C	donor_gain	1.0000
9:109381651:CTGAT:C	donor_gain	1.0000
9:109381783:CAGCA:C	acceptor_gain	1.0000
9:109381785:GCA:G	acceptor_gain	1.0000
9:109381786:CA:C	acceptor_gain	1.0000
9:109381786:CAC:C	acceptor_gain	1.0000
9:109381788:C:CC	acceptor_gain	1.0000
9:109381789:T:C	acceptor_loss	1.0000
9:109382296:CCATA:C	donor_loss	1.0000
9:109382297:CATAC:C	donor_loss	1.0000
9:109382298:ATACC:A	donor_loss	1.0000
9:109382299:TACCT:T	donor_loss	1.0000
9:109382300:A:C	donor_loss	1.0000
9:109382301:C:CA	donor_loss	1.0000
9:109382443:CCGGT:C	acceptor_gain	1.0000
9:109382444:CGGT:C	acceptor_gain	1.0000
9:109382444:CGGTC:C	acceptor_gain	1.0000
9:109382446:GTC:G	acceptor_loss	1.0000
9:109382447:TC:T	acceptor_loss	1.0000
9:109383417:GCTCA:G	donor_loss	1.0000
9:109383418:CTCAC:C	donor_loss	1.0000

AlphaMissense

6018 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:109382403:C:A	W809C	1.000
9:109382403:C:G	W809C	1.000
9:109382405:A:G	W809R	1.000
9:109382405:A:T	W809R	1.000
9:109383546:T:A	K753N	1.000
9:109383546:T:G	K753N	1.000
9:109383547:T:A	K753I	1.000
9:109406479:A:G	L592P	1.000
9:109406485:A:G	L590P	1.000
9:109408377:C:G	G527R	1.000
9:109408377:C:T	G527R	1.000
9:109410009:A:G	F523S	1.000
9:109410012:C:T	G522E	1.000
9:109379609:C:G	A897P	0.999
9:109379619:A:C	F893L	0.999
9:109379619:A:T	F893L	0.999
9:109379621:A:G	F893L	0.999
9:109379627:A:C	Y891D	0.999
9:109381675:G:T	R881S	0.999
9:109381683:C:G	R878P	0.999
9:109381767:C:T	G850D	0.999
9:109381768:C:G	G850R	0.999
9:109381774:G:C	R848G	0.999
9:109381776:C:T	G847D	0.999
9:109381777:C:G	G847R	0.999
9:109381782:C:T	G845E	0.999
9:109381783:C:G	G845R	0.999
9:109381783:C:T	G845R	0.999
9:109381785:G:T	A844D	0.999
9:109382304:G:C	C842W	0.999

dbSNP variants (sampled 300 via entrez): RS1000067520 (9:109399262 A>G,T), RS1000070057 (9:109424100 G>A,T), RS1000125312 (9:109428555 G>A), RS1000126508 (9:109467796 G>A), RS1000127083 (9:109438909 T>C), RS1000141272 (9:109479010 T>A,G), RS1000152166 (9:109434166 C>G,T), RS1000185234 (9:109434448 C>G), RS1000209887 (9:109514046 G>C), RS1000236433 (9:109473543 C>A,G,T), RS1000251839 (9:109451790 C>G), RS1000261713 (9:109432846 T>A), RS1000262387 (9:109514319 G>A,T), RS1000300708 (9:109462596 G>A), RS1000303494 (9:109520768 G>A)

Disease associations

OMIM: gene MIM:176877 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (2): prostate cancer (MONDO:0008315), schizophrenia (MONDO:0005090)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

8 total (8 of 8 shown, HPO-id order):

HPO	Term
HP:0000952	Jaundice
HP:0000989	Pruritus
HP:0001945	Fever
HP:0002027	Abdominal pain
HP:0002039	Anorexia
HP:0011985	Acholic stools
HP:0012378	Fatigue
HP:0100574	Biliary tract neoplasm

GWAS associations

36 associations (top):

Study	Trait	p-value
GCST003182_3	Staphylococcus aureus nasal carriage (persistent)	8.000000e-07
GCST004379_3	Red blood cell density in sickle cell anemia	1.000000e-06
GCST004409_1	HIV-associated neurocognitive disorder	1.000000e-07
GCST004410_2	HIV-associated neurocognitive disorder (asymptomatic neurocogntive impairment)	5.000000e-06
GCST004411_1	HIV-associated neurocognitive disorder (mild neurocognitive disorder or asymptomatic neurocognitive impairment)	2.000000e-07
GCST005173_78	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes	9.000000e-06
GCST005175_19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes	7.000000e-06
GCST005988_9	Serum albumin levels	2.000000e-09
GCST007740_22	Iris color (a* coordinate)	9.000000e-06
GCST007741_42	Iris color (b* coordinate)	9.000000e-07
GCST007876_110	Estimated glomerular filtration rate	1.000000e-08
GCST010244_206	Triglyceride levels	1.000000e-08
GCST010796_151	Electrocardiogram morphology (amplitude at temporal datapoints)	6.000000e-09
GCST010796_152	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-09
GCST010796_153	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010796_154	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-09
GCST010796_155	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-10
GCST010796_156	Electrocardiogram morphology (amplitude at temporal datapoints)	6.000000e-10
GCST010796_157	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-09
GCST010796_158	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-10
GCST010796_159	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-09
GCST010796_160	Electrocardiogram morphology (amplitude at temporal datapoints)	7.000000e-09
GCST010796_161	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-08
GCST010796_162	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_163	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_164	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-08
GCST010796_165	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_167	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_168	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-08
GCST010796_169	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0007757	persistent Staphylococcus aureus carrier status
EFO:0007948	HIV-associated neurocognitive disorder
EFO:0007983	asymptomatic neurocognitive impairment
EFO:0007982	mild neurocognitive disorder
EFO:0004723	coronary artery calcification
EFO:0009764	eye colour measurement
EFO:0004530	triglyceride measurement
EFO:0004327	electrocardiography

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2396509 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

1 measured of 2 human assays (2 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	IC50	2900 nM	US-9522881: Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)

ChEMBL bioactivities

3 potent at pChembl≥5 of 5 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.97	IC50	1070	nM	CHEMBL3319356
5.80	IC50	1600	nM	CHEMBL2396718

PubChem BioAssay actives

2 with measured affinity, of 8 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
6-hydroxy-3-iodo-1-methyl-2-[3-[[2-oxo-2-(4-thiophen-3-ylanilino)acetyl]amino]phenyl]indole-5-carboxylic acid	1182543: Inhibition of PTPH1 (unknown origin)	ic50	1.0700	uM
3-[2-(3-chlorophenyl)ethynyl]-6-hydroxy-2-[4-[2-oxo-2-(propylamino)ethoxy]phenyl]-1-benzofuran-5-carboxylic acid	755772: Inhibition of recombinant PTPH1 (unknown origin) using pNPP as substrate by spectrophotometric analysis	ic50	1.6000	uM

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	8
Tretinoin	affects expression, decreases expression, increases expression	4
Acetaminophen	decreases expression, increases expression	3
Benzo(a)pyrene	affects methylation, increases expression	2
Calcitriol	decreases expression, increases expression	2
Cyclosporine	increases expression, increases methylation	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
N(6)-(delta(2)-isopentenyl)adenine	decreases expression	1
methylmercuric chloride	increases expression	1
bisphenol A	decreases methylation	1
2-butenal	decreases expression	1
hydroxyhydroquinone	decreases expression, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
coumarin	decreases phosphorylation	1
4-aminobenzhydrazide	decreases reaction, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
tamibarotene	affects expression	1
CGP 52608	affects binding, increases reaction	1
pirfenidone	affects binding, decreases reaction, increases reaction, decreases phosphorylation	1
entinostat	increases expression	1
cotylenin A	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
clothianidin	increases expression	1
belinostat	decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2401194	Binding	Inhibition of recombinant PTPH1 (unknown origin) using pNPP as substrate by spectrophotometric analysis	A potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases. — J Med Chem

Cellosaurus cell lines

6 cell lines: 6 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_1543	NCI-H2228	Cancer cell line	Female
CVCL_4V13	NCI-H2228-Luc	Cancer cell line	Female
CVCL_E3I6	HyCyte NCI-H2228-Luc	Cancer cell line	Female
CVCL_E6DB	NCI-H2228-ARY	Cancer cell line	Female
CVCL_TH61	HAP1 PTPN3 (-) 1	Cancer cell line	Male
CVCL_TH62	HAP1 PTPN3 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

600 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety